The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse - 25/08/11
Doi : 10.1016/j.jaad.2003.10.509
Craig L Leonardi, MD a, Boni Elewski, MD b, Charles Camisa, MD c, Ralph Zitnik, MD d
a Saint Louis University, Saint Louis, MO, United States USA
b University of Alabama at Birmingham, Birmingham, AL, United States USA
c Cleveland Clinic Foundation, Department of Dermatology, Naples, FL, United States USA
d Amgen Inc., Thousand Oaks, CA, United States USA
 | Sponsored by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth. |
© 2004
Publié par Elsevier Masson SAS.
Vol 50 - N° 3S
P. P146 - mars 2004 Retour au numéro
Article précédent
- Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response
- Alice B Gottlieb, Kenneth Gordon, Andrea Wang, Ralph Zitnik
- Mechanisms of disease: angiogenesis, vascular endothelial growth factor (VEGF) and psoriasis
- Helen S Young, Angela Summers, Paul Brenchley, Christopher Griffiths
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?